An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

- Locally advanced or metastatic disease; locally advanced disease must not be amenable
to resection with curative intent

- Part 1: Subjects with advanced or metastatic solid tumors

- Part 2: Subjects with advanced or metastatic adenocarcinoma of endometrium, melanoma,
non-small cell lung cancer, and renal cell carcinoma

- Subjects who have disease progression after treatment with available therapies that
are known to confer clinical benefit, or who are intolerant to treatment, or subjects
who refuse standard treatment

- Presence of measureable disease based on RECIST v1.1

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

Exclusion Criteria:

- Laboratory and medical history parameters not within the protocol-defined range

- Receipt of anticancer medications or investigational drugs within protocol-defined
intervals before the first administration of study drug

- Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or
complications from prior surgical intervention before starting therapy

- Receipt of a live vaccine within 30 days of planned start of study therapy

- Active autoimmune disease

- Prior treatment with any tumor necrosis factor super family agonist

- Known active central nervous system metastases and/or carcinomatous meningitis

- Evidence of active, noninfectious pneumonitis or history of interstitial lung disease

- Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation